{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:38:03Z","timestamp":1791333483164,"version":"4.3.1"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:sec id=\"ab-eoi220049-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Thyroid eye disease (TED) results in varying degrees of proptosis and diplopia negatively affecting quality of life (QoL), producing possibly substantial visual changes, disfigurement, and disability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220049-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the association of varying TED severities with QoL in a non-TED population by assessing health state utility scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220049-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This qualitative study, conducted from April 20, 2020, to April 29, 2021, assessed health states for active, moderate-severe TED, and values were elicited using time trade-off methods. Six health states of varying severity were determined from 2 placebo-controlled clinical trials (171 patients with TED and clinical activity score \u22654, \u00b1diplopia\/proptosis) and refined using interviews with US patients with TED (n\u2009=\u20096). Each health state description was validated by interviews with additional TED patient advocates (n\u2009=\u20093) and physician experts (n\u2009=\u20093). Health state descriptions and a QOL questionnaire were piloted and administered to a general population. Visual analog scales (VASs) were also administered to detect concurrence of the findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220049-7\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>\n                      TED health state utility scores and whether they differ from one another were assessed using Shapiro-Wilk, Kruskal-Wallis, pairwise Wilcoxon rank sum, and paired\n                      <jats:italic>t<\/jats:italic>\n                      tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220049-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 111 participants completed time trade-off interviews. The mean (SD) utility value was 0.44 (0.34). The lowest (worse) mean utility value was observed in the most severe disease state (constant diplopia\/large proptosis) with 0.30 (95% CI, 0.24-0.36), followed by constant diplopia\/small proptosis (0.34; 95% CI, 0.29-0.40), intermittent or inconstant diplopia\/large proptosis (0.43; 95% CI, 0.36-0.49), no diplopia\/large proptosis (0.46; 95% CI, 0.40-0.52), and intermittent or inconstant diplopia\/small proptosis (0.52; 95% CI, 0.45-0.58). The highest (best) mean value, 0.60 (95% CI, 0.54-0.67), was observed for the least severe disease state (no diplopia\/small proptosis).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi220049-9\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>These findings suggest that patients with active, moderate-severe TED may have substantial disutility, with increasing severity of proptosis\/diplopia more likely to have detrimental associations with QoL. These health state scores may provide a baseline for determining QoL improvement in these TED health states (utility gains) treated with new therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2022.3225","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T11:32:26Z","timestamp":1672313546000},"page":"159","source":"Crossref","is-referenced-by-count":25,"title":["Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States"],"prefix":"10.1001","volume":"141","author":[{"given":"Terry J.","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, Ann Arbor, Michigan"},{"name":"Division of Metabolism, Endocrine and Diabetes, Michigan Medicine and University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Cockerham","sequence":"additional","affiliation":[{"name":"Stanford Department of Ophthalmology, Palo Alto, California"},{"name":"Central Valley Eye Medical Group, Stockton, California"},{"name":"Senta Clinic, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Lelli","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Choudhary","sequence":"additional","affiliation":[{"name":"Kansas University Medical Center, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Taylor","sequence":"additional","affiliation":[{"name":"Horizon Therapeutics, Deerfield, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naina","family":"Barretto","sequence":"additional","affiliation":[{"name":"Horizon Therapeutics, Deerfield, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Enstone","sequence":"additional","affiliation":[{"name":"Adelphi Values PROVE, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Oliver","sequence":"additional","affiliation":[{"name":"Adelphi Values PROVE, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judah","family":"Lynch","sequence":"additional","affiliation":[{"name":"Adelphi Values PROVE, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Holt","sequence":"additional","affiliation":[{"name":"Horizon Therapeutics, Deerfield, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"eoi220049r1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.beem.2011.10.005","article-title":"Epidemiology of Graves\u2019 orbitopathy (GO) and relationship with thyroid disease.","volume":"26","author":"Lazarus","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"7","key":"eoi220049r2","first-page":"5425","article-title":"Prevalence and associated factors for thyroid eye disease (TED) in the AAO IRIS registry.","volume":"61","author":"Hyman","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"eoi220049r3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000260224","article-title":"Thyroid eye disease: pathogenesis and treatment.","volume":"224","author":"Sikder","year":"2010","journal-title":"Ophthalmologica"},{"issue":"12","key":"eoi220049r4","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1210\/jc.2006-1402","article-title":"Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype.","volume":"91","author":"Manji","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"eoi220049r5","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy.","volume":"362","author":"Bahn","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"eoi220049r6","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.eprac.2022.06.003","article-title":"Inflammatory and noninflammatory thyroid eye disease: comparison of disease signs, symptoms, and quality of life in US patients.","volume":"28","author":"Wang","year":"2022","journal-title":"Endocr Pract"},{"issue":"1","key":"eoi220049r7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/01.wno.0000347033.35456.80","article-title":"Oxford handbook of ophthalmology.","volume":"29","author":"Cook","year":"2009","journal-title":"J Neuroophthalmol"},{"key":"eoi220049r8","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1055\/s-0029-1212177","article-title":"The relevance of physical and psychosocial factors for the quality of life in patients with thyroid-associated orbitopathy (TAO).","volume":"107","author":"Egle","year":"1999","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"17","key":"eoi220049r9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3238\/arztebl.2009.0283","article-title":"Quality of life and occupational disability in endocrine orbitopathy.","volume":"106","author":"Ponto","year":"2009","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"eoi220049r10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/archopht.123.4.491","article-title":"Psychological disturbance in graves ophthalmopathy.","volume":"123","author":"Farid","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"eoi220049r11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/105072502753600205","article-title":"Psychosocial factors in subjects with thyroid-associated ophthalmopathy.","volume":"12","author":"Kahaly","year":"2002","journal-title":"Thyroid"},{"issue":"6","key":"eoi220049r12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from 2 randomised, double-masked, placebo-controlled, multicentre trials.","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"eoi220049r13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease.","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"eoi220049r14","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy.","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"eoi220049r15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40273-016-0404-1","article-title":"EuroQol protocols for time trade-off valuation of health outcomes.","volume":"34","author":"Oppe","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"eoi220049r18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldq033","article-title":"Health outcomes in economic evaluation: the QALY and utilities.","volume":"96","author":"Whitehead","year":"2010","journal-title":"Br Med Bull"},{"issue":"11","key":"eoi220049r19","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states.","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"issue":"3","key":"eoi220049r22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11136-020-02650-y","article-title":"US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples.","volume":"30","author":"Jiang","year":"2021","journal-title":"Qual Life Res"},{"issue":"6","key":"eoi220049r23","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s10198-017-0931-5","article-title":"Experience-based utility and own health state valuation for a health state classification system: why and how to do it.","volume":"19","author":"Brazier","year":"2018","journal-title":"Eur J Health Econ"},{"issue":"9","key":"eoi220049r24","doi-asserted-by":"publisher","first-page":"A483","DOI":"10.1016\/j.jval.2017.08.479","article-title":"Health state utilities in individuals with goiter, hypothyroidism, hyperthyroidism and Graves\u2019 disease as an example for thyroid disorders: a systematic review.","volume":"20","author":"Mladenovic","year":"2017","journal-title":"Value Health"},{"issue":"1","key":"eoi220049r25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/archopht.118.1.47","article-title":"Utility values and age-related macular degeneration.","volume":"118","author":"Brown","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"eoi220049r26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1136\/bjo.85.3.327","article-title":"Utility values associated with blindness in an adult population.","volume":"85","author":"Brown","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"eoi220049r27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ajo.2019.06.005","article-title":"Time trade-off utility values in noninfectious uveitis.","volume":"208","author":"Niemeyer","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"eoi220049r28","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa140","article-title":"Trends in treatment of active, moderate-to-severe thyroid eye disease in the US.","volume":"4","author":"Wang","year":"2020","journal-title":"J Endocr Soc"},{"key":"eoi220049r16","volume-title":"Time Trade-off User Manual: Props and Self-Completion Methods","author":"Gudex","year":"1994"},{"key":"eoi220049r20","volume-title":"NICE DSU Technical Support Document 11: Alternatives to EQ-5D for Generating Health State Utility Values","author":"Brazier","year":"2011"},{"key":"eoi220049r17","unstructured":"Tolley? K. What are health utilities? Accessed June 1, 2021. http:\/\/www.bandolier.org.uk\/painres\/download\/What%20is%202009\/What_are_health_util.pdf"},{"key":"eoi220049r21","unstructured":"R Core Team. The R project for statistical computing. Accessed June 1, 2021. http:\/\/www.R-project.org\/"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2800106\/jamaophthalmology_smith_2022_oi_220049_1675440855.00745.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T11:02:14Z","timestamp":1676545334000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2800106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.3225","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}